AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101 for pulmonary hypertension.

Credit: Marko Aliaksandr / Shutterstock.com Verastem Oncology’s combination therapy has shown durability in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data, presented during ...

Sparian Biosciences has begun a Phase I study of SBS-147, an AEAr agonist under development for the treatment of both acute and chronic pain.

Takeda is currently evaluating mezagitamab’s potential in two late-stage autoimmune trials in platelet disorder, ITP and kidney disease, IgAN.

Hemispherian has initiated a first-in-human Phase I/IIa trial of its oral small molecule, GLIX1, in patients with recurrent and progressive GBM and other high-grade gliomas.

GBM is the most common and aggressive primary brain cancer. Credit: create jobs 51 / Shutterstock.com. The Global Coalition for Adaptive Research (GCAR) and Purdue Pharma have announced the activation ...

An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator (DTA) has invited the first participants to clinics for tests, with the aim to ...

Analysts were unsurprised that Brinsupri didn't best placebo's efficacy in HS – mainly due to a lack of evidence supporting this MoA in this disease.

Credit: Below the Sky / Shutterstock.com Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic dermatitis failed to show benefit.

TRiCares' pivotal trial will build on an ongoing early feasibility study of the Topaz TTVR system that began in January 2025.

CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab along with chemoimmunotherapy as a second-line treatment for patients with unresectable or ...

Alar’s ketamine-based drug mitigates certain adverse events, which could eliminate the need for post-dose monitoring.